Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Aug 22.
Published in final edited form as: European J Org Chem. 2018 Apr 17;2018(24):3139–3143. doi: 10.1002/ejoc.201800557

β-Carbolinone Analogues from the Ugi Silver Mine

Rudrakshula Madhavachary a,#, Naganaboina Naveen a,#, Yuanze Wang a, Qian Wang a, Markella Konstantinidou a, Alexander Dömling a
PMCID: PMC6706090  NIHMSID: NIHMS998164  PMID: 31440115

Abstract

Here we describe a facile, tandem synthetic route for β-carbolinones, a class of natural products of high biological significance. Commercially available building blocks yield highly diverse analogues in just two simple steps.

Keywords: Ugi-reaction, Multicomponent reactions, Isocyanide, B-Carboline, Propargyl

Introduction

Synthetic strategies to obtain natural products, and analogues/skeletons thereof, are at the very heart of synthetic organic chemistry.[1] Approaches achieving atom economy are highly sought after, offering various advantages, minimization of waste, time and resources. Multicomponent reaction chemistry is such a group of synthetic transformations allowing via short synthetic routes, access to large libraries of analogues of many different scaffolds from common building blocks, finally minimizing waste, time and resources.[2] Natural products containing the β-carbolinone scaffold show diverse biological and pharmacological activities,[3] such as anticancer, inhibition of human leukocyte elastase, and the modulation of effects associated with depression, anxiety disorders and muscle spasms, just to name a few.[4]

Conventional methods towards the synthesis of β-carbolin-one analogues require multiple steps, including complicated steps to prepare starting materials.[5] To access this significant scaffold, methods such as dehydrogenative annulations,[6a] intramolecular Heck,[6b] and cycloisomerization[6c] were established. Recently, a silver-catalyzed oxidative cyclization of prop argylamide-substituted indoles towards phosphorated indolo-azepinones was described.[6d] On the other hand, Ugi adducts are easily accessible, however, transforming such adducts into potentially biologically active molecules remains challenging, even in light of considerable recent advances.[7] In particular, the use of propargylamine as an amine source in Ugi-reactions is limited to date. Recently, propargylamine was used as the amine component in an Ugi reaction, and via a three-step synthesis using palladium catalyzed cyclization, resulted in aza-polyheterocycles.[7b] Moreover, Eycken and co-workers developed a gold-catalyzed approach for the synthesis of cyclo-pentapyridinones and spirocyclopentapyridinones using prop-argylamine as an amine source.[7c] The same group recently described a gold-catalyzed synthesis of pyrrolopyridines and azepinoindoles starting from propargylamines.[7d] Chauhan and co-workers described interesting β-carbolinone and indolo-pyrazinone analogues based on an Ugi-four-component reaction (Ugi-4CR) with aminodimethylacetal as amine source. However, this reaction requires stoichiometric amounts of PTSA and it produces a side product along with the β-carbolinones.[8] Synthesis of oxopyrazino[1,2-a] indoles was developed by the Shafiee group using potassium tert-butoxide, in which cyclization takes place at the more nucleophilic nitrogen of the Ugi product, resulting in oxopyrazino[1,2-a]indoles (Scheme 1).[9] Although the above methods are useful, there is still room for improvement regarding the establishment of a mild synthetic approach with high diversity for the β-carbolinone scaffold.

Scheme 1.

Scheme 1.

Synthesis of carbolinones: present and previous work.

Here, our aim is to use propargylamine in Ugi-four-component reactions followed by a tandem/sequential AgOTf-catalyzed carbocyclization of the Ugi-products towards β-carbolin-one analogues. In this synthetic approach, 6-exo-dig carbocylization takes place to form the six-membered indole annulated pyrido-1-one in fair to very good yields.

Results and Discussion

Isocyanide-based multicomponent reactions (IMCRs) have attracted a lot of attention, due to the fact that versatile functional groups can be introduced in the MCR adducts, which can undergo further condensations or cyclizations reactions leading to an array of structurally diverse scaffolds.[10] In this study, starting from the Ugi-4CR of propargylamine 1a as an amine source, benzaldehyde 2a, indole-2-carboxylic acid 3a and tert-butyl isocyanide 4a in methanol at room temperature resulted to the corresponding Ugi adduct 5a in a good yield of 83 % after 12 h. With compound 5a in hand, we were keen to investigate the intramolecular hydroarylation. The initial investigation with Al(OTf )3 (20 mol-%) in CH3CN at 75 °C gave the desired product 6a but in a low yield of 21 %, whereas no product was detected with CuI, PTSA, TfOH, KOTf, and NaOTf. On the other hand, the usage of ZnCl2 as Lewis-acid catalyst (20 mol-%) led to an isolated yield of 6a in 40 %. The application of catalysts like Sn(OTf )2, In(OTf )3, Zn(OTf )2 in the reaction at 75 °C gave the isolated yield of 42 %, 56 %, and 56 % respectively. Finally, the yield was increased to 75 % when the reaction was carried out in the presence of AgOTf (20 mol-%) at 75 °C (Table 1, entry 11). After selecting the catalyst, we extensively screened different solvents to achieve the best conditions. A one-pot cyclization was also explored since it could add considerable value to our synthetic approach. To our delight, using methanol as a solvent for 12 h at room temperature for the Ugi reaction and then adding AgOTf (20 mol-%) and heating the reaction mixture to 75 °C for 3 h was proven to be the best condition (Table 1, entry 15).

Table 1.

Optimization of the intramolecular hydroarylation.[a,b]

graphic file with name nihms-998164-t0004.jpg
[a]

The Ugi-reaction was carried out using 1a (1.0 mmol), 2a (1.0 mmol), 3a (1.0 mmol) and 4a (1.0 mmol) in MeOH for 12 h at room temperature. Pure product 5a was subjected to cyclization under indicated catalysis in a sealed tube with an indicated solvent for 3 h at 75 °C.

[b]

Isolated yield.

[c]

Reaction was carried out one-pot (Ugi-reaction followed by cyclization).

With the optimized one-pot reaction conditions in hand, the scope of the “Ugi-4CR/cyclization” reaction was further investigated by reacting propargylamine with different aldehydes/ket-ones, isocyanides and indole-2-carboxylic acid in methanol followed by AgOTf catalyzed cyclization to furnish the corresponding β-carbolinone library 6av. All the substrates 1, 2, 3 and 4 led to the expected β-carbolinone products 6av in 49–77 % yields in one-pot. Substituted benzyl isocyanides with electron-donating groups like p-methoxy (4b), 3,4,5-trimethoxy (4d) reacted smoothly with 65 % and 63 % yields, respectively. Electron withdrawing substituents like cyano and chloro reacted nicely to give the cyclized products in good yields (6c, 6e, Table 2). The commercially available 5-chloro substituted indole-2-carboxylic acid (3i) reacted to give the expected product 6i in 59 % yield. Similarly, 2,6-dimethyl benzyl isocyanide and aliphatic branched isocyanides also furnished the different β-carbolinone products in good yields. Table 2 clearly indicates that there are no electronic or steric effects on the outcome of the reaction.

Table 2.

Synthesis of β-carbolinones: Variation in isocyanide part.[a,b]

graphic file with name nihms-998164-t0005.jpg
[a]

The reactions were run using 1a (1.0 mmol), 2b (1.0 mmol), 3 (1.0 mmol) and 4ai (1.0 mmol) in MeOH as solvent for 12–24 h at room temperature. After Ugi-reaction, AgOTf (20 mol-%) followed by extra MeOH was added to the reaction mixture and the whole mixture was heated to 75 °C for 3 h in a sealed tube.

[b]

Isolated yield.

After successfully demonstrating the one-pot cyclization reactions with different isocyanides, we then focused on different aldehydes and ketones. As shown in Table 3, also, in this case, the one-pot approach results in very good yields. For instance, in case of ortho/para bromo-substituted benzaldehydes, the corresponding products were obtained in 77 % and 67 % yields respectively, which unlocks interesting opportunities for further functionalization of the bromo-products via palladium catalysis (Table 3, 6j, 6k). Furthermore, keeping in mind the intriguing physicochemical properties of fluoro and trifluoromethyl substituents, we intentionally performed the reactions with 2l, 2m and 2n to get the desired products in good yields (Table 3, 6l, 6m, 6n). Strong +M groups, as well as –M groups containing benzaldehydes, reacted well to give fair yields (Table 3, 6p, 6q, 6r, 6s, 6t). Even aliphatic aldehyde also efficiently (2u) reacted to give 70 % yield of expected cyclized product 6u. It is worth mentioning that cyclic ketone reacted without any interruption to obtain decent yield (Table 3, 6v).

Table 3.

Synthesis of β-carbolinones: Variation in aldehyde/ketone part.[a,b]

graphic file with name nihms-998164-t0006.jpg
[a]

The reactions were run using 1a (1.0 mmol), 2 (1.0 mmol), 3a (1.0 mmol) and 4a (1.0 mmol) in MeOH as solvent for 12–24 h at room temperature. After Ugi-reaction, AgOTf (20 mol-%) followed by extra MeOH was added to the reaction mixture and the whole mixture was heated to 75 °C for 3 h in a sealed tube.

[b]

Isolated yield.

A plausible mechanism of the cyclization path was explained based on the previous reports as shown in Scheme 2.[11] After getting the Ugi adduct, silver attacks the alkyne to give the intermediate A, which undergoes a 6-exo-dig cyclization to give intermediate B, which upon rearomatization/protodemetalation gives the β-Carbolinone product 6.

Scheme 2.

Scheme 2.

Anticipated mechanistic pathway for 6-exo-dig cyclization reaction.

As already mentioned, β-carbolinones possess diverse biological activities and evident from the report by Bracher et al. in 2011.[12] Derivatives of 7,8-dichloro-1-oxo-β-carbolinones, which were based on the alkaloid Bauerine C showed kinase inhibitory activity. A co-crystal structure with DAPK3 was obtained, shedding light into the molecular interactions and indicating an unusual, non-ATP mimetic binding mode. Using the PDB code 3BHY, we were interested in docking our β-carbolin-one derivatives. Interestingly, we observed a good overlap of the indole parts with the original ligand and our compounds fitted nicely into the pocket. Although in the original crystal structure, the two chloro substituents of the indole ring participate in halogen bonds, this feature is missing from our derivatives. However, in our case, the indole rings are oriented in a similar manner and the amide moieties of the side chains were able to form hydrogen bonds. Halogen bonds are weaker than the hydrogen bonds that we observed while docking the compounds and we thus hypothesize that these compounds could have potential as kinase inhibitors (Figure 1).

Figure 1.

Figure 1.

Docking poses. Up left: Overlap of compound 6p (yellow sticks) with the ligand (green sticks) of PDB 3BHY. Up right: hydrogen bonds (black dots) of compound 6p (yellow sticks) with Lys141 and Ser21 (cyan sticks). Below: 2D structures of ligand of PDB 3BHY and compound 6p.

Conclusions

To sum up, we have successfully established a mild and facile one-pot procedure for the synthesis of β-carbolinones, starting from commercially available starting materials. Diversity can be achieved mainly through, the isocyanide and the aldehyde component and to a smaller extent the indole-carboxylic acid. Regarding potential applications, docking studies indicate that these types of derivatives could be useful as kinase inhibitors and biological work is ongoing, will be reported in due course.

Supplementary Material

2

Acknowledgments

The work was financially supported from the NIH (NIH 2R01GM097082-05) and by the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115489, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. Funding was received from the European Union’s Horizon 2020 research and innovation programme under MSC ITN “Accelerated Early stage drug dIScovery” (AEGIS, grant agreement No 675555) and Co-Funds ALERT (grant agreement No 665250) and ProminenT (grant agreement No 665250) and Dutch Cancer Society (KWF grant agreement No 10504). Dr. N. N. thanks, NAMASTE postdoc fellowship, Erasmus Mundus.

Footnotes

Conflict of Interest

The authors declare no conflict of interest.

References

  • [1].a) Gaich T, Baran PS, J. Org. Chem 2010, 75, 4657; [DOI] [PubMed] [Google Scholar]; b) Wender PA, Nat. Prod. Rep 2014, 31, 433; [DOI] [PubMed] [Google Scholar]; c) Zarganes-Tzitzikas T, Chandgude AL, Dömling A, Chem. Rec 2015, 15, 981. [DOI] [PubMed] [Google Scholar]
  • [2].a) Dömling A, Ugi I, Angew. Chem. Int. Ed 2000, 39, 3168; Angew. Chem. 2000, 112, 3300; [DOI] [PubMed] [Google Scholar]; b) Dömling A, Chem. Rev 2006, 106, 17; [DOI] [PubMed] [Google Scholar]; c) Dömling A, Wang W, Wang K, Chem. Rev 2012, 112, 3083; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Ramachary DB, Jain S, Org. Biomol. Chem 2011, 9, 1277. [DOI] [PubMed] [Google Scholar]
  • [3].Larsen LK, Moore RE, Patterson GML, J. Nat. Prod 1994, 57, 419; [DOI] [PubMed] [Google Scholar]; b) Cincinelli R, Cassinelli G, Dallavalle S, Lanzi C, Merlini L, Botta M, Tuccinardi T, Martinelli A, Penco S, Zunino F, J. Med. Chem 2008, 51, 7777; [DOI] [PubMed] [Google Scholar]; c) Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S, Chem. Biol 2011, 18, 67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].a) Veale CA, Damewood JR, Steelman GB, Bryant C, Gomes B, Williams J, J. Med. Chem 1995, 38, 86; [DOI] [PubMed] [Google Scholar]; b) Ritzeler O, Castro A, Grenler L, Soucy F, EP Pat 1134221 (A1), 2001; [Google Scholar]; c) Nielsch U, Sperzel M, Bethe B, Junge B, Lieb F, Velten R, DE Pat 19807993 (A1), 1999; [Google Scholar]; d) Menta E, Pescalli N, Spinelli S, WO Pat 2001/009129, 2001; [Google Scholar]; e) Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Francon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B, CNS Drug Rev 2003, 9, 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].a) Bracher F, Hildebrand D, Liebigs Ann. Chem 1992, 26, 1315; [Google Scholar]; b) Hu YF, Wang SZ, Ge ZM, Shi HJ, Lu J, CN. Patent 1611500A, 2003; [Google Scholar]; c) Tahri A, Buysens KJ, Van der Eycken EV, Vandenberghe DM, Hoornaert GJ, Tetrahedron 1998, 54, 13211; [Google Scholar]; d) Lin G, Wang Y, Zhou Q, Tang W, Wang J, Lu T, Molecules 2010, 15, 5680; [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Prasad TRN, Kumara Swamy KC, Org. Biomol. Chem 2016, 14, 4519 and references cited therein. [DOI] [PubMed] [Google Scholar]
  • [6].a) Shi Z, Cui Y, Jiao N, Org. Lett 2010, 12, 2908; [DOI] [PubMed] [Google Scholar]; b) Baccalli EM, Broggini G, Marchesini A, Rossi E, Tetrahedron 2002, 58, 6673; [Google Scholar]; c) England DB, Padwa A, Org. Lett 2008, 10, 3631 and references cited therein; [DOI] [PubMed] [Google Scholar]; d) Hua HL, Zhang BS, He YT, Qiu YF, Wu XX, Xu PF, Liang YM, Org. Lett 2016, 18, 216. [DOI] [PubMed] [Google Scholar]
  • [7].a) Marcaccini S, T. Torroba in Post-Condensation Modifications of the Passerini and Ugi Reactions, in Multicomponent Reactions (Eds.: Zhu J and Bienaymé H), Wiley-VCH, Weinheim (Germany), 2005, Ch. 2; [Google Scholar]; b) Garcia-Gonzalez MC, Hernandez-Vazquez E, Gordillo-Cruz RE, Miranda LD, Chem. Commun 2015, 51, 11669; [DOI] [PubMed] [Google Scholar]; c) Dipak DV, Galli M, Jacobs J, Van Meer-velt L, Van der Eycken EV, Chem. Commun 2013, 49, 7171; [DOI] [PubMed] [Google Scholar]; d) Kumar A, Vachhani DD, S. G. Modha, S. K. Sharma, Parmar VS, Van der Eycken EV, Eur. J. Org. Chem 2013, 2288.
  • [8].Purohit P, Pandey AK, Kumar B, Chauhan PMS, RSC Adv 2016, 6, 21165. [Google Scholar]
  • [9].Mahdavi M, Hassanzadeh-Soureshjan R, Saeedi M, Ariafard A, Ah-madi RB, Ranjbar PR, Shafiee A, RSC Adv 2015, 5, 101353. [Google Scholar]
  • [10].a) Koopmanschap G, Ruijter E, Orru RVA, Beilstein J. Org. Chem 2014, 10, 544; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Orru RVA, de Greef M, Synthesis 2003, 1471;; c) Bien-ayme H, Hulme C, Oddon G, Schmitt P, Chem. Eur. J 2000, 6, 3321. [DOI] [PubMed] [Google Scholar]
  • [11].a) Feng X, Wang H-Q, Yang B, Fan R-H, Org. Lett 2014, 16, 3600; [DOI] [PubMed] [Google Scholar]; b) Fanga G, Bi X, Chem. Soc. Rev 2015, 44, 8124; [DOI] [PubMed] [Google Scholar]; c) Hao L, Pan Y-G, Wang T, Lin M, Chen L, Zhan Z-P, Adv. Synth. Catal 2010, 352, 3215; [Google Scholar]; d) Li Z, Kumar A, Sharma SK, Parmar VS, Van der Eycken EV, Tetrahedron 2015, 71, 3333. [Google Scholar]
  • [12].Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S, Bracher F, J. Med. Chem 2012, 55, 403. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

2

RESOURCES